Averna Therapeutics
Tracy DiMezzo is an experienced professional in the biotechnology field, currently serving as Senior Director at Averna Therapeutics since March 2025. Prior to this role, Tracy held the position of Director and Head of Production at Orna Therapeutics from October 2022 to March 2025, and Associate Director of Process Development at Resilience from June 2021 to October 2022. Tracy's career began at Intellia Therapeutics, Inc., where Tracy was both Associate Director and Senior Scientist from July 2016 to March 2022. Tracy holds a Master of Science degree from the University of Illinois Springfield and a Bachelor of Science degree in Biochemistry from Albright College.
This person is not in any teams
This person is not in any offices
Averna Therapeutics
Averna Therapeutics is a biotechnology company developing Ribonucleic acid (RNA) and lipid nanoparticle (LNP)-based genomic medicines to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Our proprietary technology is based on a natural system and inserts therapeutic genetic instructions into “safe harbor” sites in the genome – genomic regions that allow stable gene integration without disrupting normal cell function. Because our medicines are encoded in RNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent. Follow us on LinkedIn and stay in touch as we seek to advance develop RNA/LNP-based genomic medicines that deliver meaningful solutions for patients!